| ［1］ Algaba F. Rereading the renal cell tumors［J］. Int J Surg Pathol, 2010, 18(3): 9497. DOI: 10.1177/1066896910370468. ［2］ Hase S, Weinitschke K, Fischer K, et al. Monitoring perioperative immune suppression in renal cancer patients［J］. Oncol Rep, 2011, 25(5): 14551464. DOI: 10.3892/or.2011.1199. ［3］ 王欢, 周芳坚, 王其京, 等. 负载自体肿瘤细胞裂解物的DC疫苗联合CIK治疗晚期肾癌的临床观察附10例报告［J］. 癌症, 2006, 25(5): 625630. DOI: 10.3321/j.issn:1000467X.2006.05.021. ［4］ GrossGoupil M, Massard C, Ravaud A, Targeted therapies in metastatic renal cell carcinoma: overview of the past year［J］. Curr Urol Rep, 2012, 13(1): 1623. DOI: 10.1007/s119340110232y. ［5］ Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomized trials［J］. BJU Int, 2011, 108(10): 15561663. DOI: 10.1111/j.1464410X.2011.10629.x. ［6］ Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma［J］. Drugs R D, 2011, 11(2): 113126. DOI: 10.2165/1159124000000000000000. ［7］ Rini BI, de La Motte Rouge T, Harzstark AL, et al. Fiveyear survival in patients with cytokinerefractory metastatic renal cell carcinoma treated with axitinib［J］. Clin Genitourin Cancer, 2013, 11(2): 107114. DOI: 10.1016/j.clgc.2012.12.004. ［8］ Weikert S, Kempkensteffen C, Busch J, et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors［J］. World J Urol, 2013, 31(4): 805809. DOI: 10.1007/s0034501106761. ［9］ Snover DC. Update on the serrated pathway to colorectal carcinoma［J］. Hum Pathol, 2011, 42(1): 110. DOI: 10.1016/j.humpath.2010.06.002. ［10］ Wehner R, Dietze K, Bachmann M, et al. The bidirectional crosstalk between human dendritic cells and natural killer cells［J］. J Innate Immun, 2011, 3(3): 258263. DOI: 10.1159/000323923. ［11］Kim JS, Chung IS, Lim SH, et al. Preclinical and clinical studies on cytokineinduced killer cells for the treatment of renal cell carcinoma［J］. Arch Pharm Res, 2014, 37(5): 559566. DOI: 10.1007/s122720140381x. ［12］李建旺, 黄春珍, 李建华, 等. 自体CIK细胞及DC细胞联合索拉非尼治疗转移性肾癌的疗效与安全性［J］. 山东医药, 2012, 52(1): 79. DOI: 10.3969/j.issn.1002266X.2012.01.004. ［13］杨茂, 郭志, 司同国, 等. 动脉栓塞联合CIK细胞对中晚期肾癌患者免疫功能的影响［J］. 临床放射学杂志, 2011, 30(3): 398401. ［14］李霞, 徐文漭, 崔静, 等. CIK细胞治疗局限性肾癌的疗效［J］. 肿瘤防治研究, 2011, 38(8): 950953. DOI: 10.3971/j.issn.10008578.2011.08.025. ［15］Huang Y, Wang Y, Li Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2［J］. J Cancer Res Clin Oncol, 2011, 137(5): 829837. DOI: 10.1007/s0043201009442. ［16］Romero AI, Chaput N, PoirierColame V, et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL15R and NKG2D triggering［J］. Cancer Res, 2014, 74(1): 6880. DOI: 10.1158/00085472.CAN131186. ［17］Morelli MB, Amantini C, Santoni M, et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells［J］. Oncotarget, 2015, 6(34): 3624536259. DOI: 10.18632/oncotarget.5768. |
